About this trial
The aim of this study is to define the importance of non-invasive programmed stimulation (NIPS) in risk stratification of ventricular tachycardia (VT) recurrence after catheter ablation and to determine the optimal treatment strategy. The primary objective is to establish whether a new VT ablation based on NIPS inducibility will reduce the risk of VT recurrence compared to antiarrhythmic drug therapy.
Eligibility criteria
Qualifiers
Patients with an implanted ICD (all brands)
Patients who underwent a successful (non-inducibility of any VT) Ventricular Tachycardia Ablation procedure, the "index procedure", supported by EnSite Precision or CARTO 3D mapping systems for the following etiologies: previous MI, myocarditis, ARVD, IDCM.
Induction of monomorphic VT at NIPS 3-7days after a successful index procedure
Age 18 years or more
Disqualifiers
Inducible VT after index procedure
Contraindication to anticoagulants
Presence of thrombi
Presence of Mitral and Aortic prosthetic valve
Trial design
Treatments tested in this trial
- Re-Do ventricular tachycardia ablation
- Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)